Navigation Links
CT and serum LDH shows promise as survival predictor for some metastatic melanoma patients
Date:4/16/2013

Combining CT imaging findings with baseline serum lactate dehydrogenase levels is showing promise as a way to predict survival in patients with metastatic melanoma being treated with anti-angiogenic therapy.

With the hope of predicting patient survival, researchers at the University of Mississippi Medical Center in Jackson and at the Ohio State University Comprehensive Cancer Center in Columbus analyzed CT images and clinical data from 46 patients with metastatic melanoma that were treated with anti-angiogenic therapy. "The analysis found that initial post-therapy CT imaging changes in tumor morphology, attenuation, size and structure (MASS Criteria) are predictive of survival. These results are similar to what we have found in patients with metastatic kidney cancer, another highly vascular tumor treated with anti-angiogenic therapy. The current study is the first of its kind to associate CT findings of tumor devascularization with survival in patients with metastatic melanoma treated with anti-angiogenic therapy," said Dr. Andrew Smith of the University of Mississippi.

"Patients with high baseline serum lactate dehydrogenase (LDH) tend to have poor overall survival compared to patients with low serum LDH," said Dr. Smith. LDH levels are used to stage metastatic melanoma, but are only weakly associated with survival when used alone," he said. "What was surprising to us was that the accuracy for predicting both progression-free and overall survival is substantially increased when MASS Criteria findings are combined with data from serum LDH levels," said Dr. Smith.

"This was an exploratory study," said Dr. Smith. "The next step is to take what we've discovered and test it in prospective clinical trials. At a minimum, patients with low baseline serum LDH and evidence of tumor devascularization on their initial post-therapy CT should be encouraged that they are likely to have a favorable response to therapy," he said.

"The hope is to identify patients that will best respond to anti-angiogenic therapy so we can improve their survival and quality of life. Patients identified as nonresponders could be offered alternative treatments to avoid unnecessary drug toxicities and cost from a therapy that will not improve their survival or quality of life," he said.

Dr. Smith's study will be presented April 17 during the ARRS Annual Meeting in Washington, DC.


'/>"/>

Contact: Samantha Schmidt
sschmidt@arrs.org
703-858-4316
American Roentgen Ray Society
Source:Eurekalert

Related medicine news :

1. Low levels of serum bilirubin spell higher lung cancer risk for male smokers
2. New - Renaissance Age Serum, a Revival in Swiss Anti-Aging Skin Care; Improve Skin Texture for a More Youthful Appearance using Gerda Spillmann’s Newest Anti-Aging Serum
3. Some minorities believe they are less likely to get cancer compared to whites, Moffitt study shows
4. Study shows severity of sleep apnea is influenced by race
5. Stanford study shows different brains have similar responses to music
6. 2-drug combo more effective in treating sarcomas, Moffitt Cancer Center study shows
7. Experimental Vaccine Shows Promise for Ovarian Cancer
8. 2-step ovarian cancer immunotherapy made from patients own tumor shows promise
9. CAMH study shows mental illness associated with heavy cannabis use
10. More Evidence Shows Hormone Therapy May Increase Breast Cancer Risk
11. New technique shows promise in restoring near vision without glasses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health ... interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), an ... education, today announce a new strategic alliance. , As CPEN’s strategic partner, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
Breaking Medicine Technology: